[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563508":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":34,"locations":24,"responsibleParty":43,"collaborators":24,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":24,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":24,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":24},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Long-Term Oxygen therapy (LTOT) then High Flow Nasal Therapy (HFNT)","2 weeks of LTOT then 2 weeks of LTOT+HFNT",[12,13],"Procedure: long-term oxygen therapy (LTOT)","Procedure: High Flow Nasal Therapy (HFNT)",{"label":15,"type":6,"description":16,"interventionNames":17},"High Flow Nasal Therapy (HFNT) then Long-Term Oxygen therapy (LTOT)","2 weeks of LTOT+HFNT then 2 weeks of LTOT",[12,13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","long-term oxygen therapy (LTOT)","Usual care with LTOT for 2 weeks",[15,9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"High Flow Nasal Therapy (HFNT)","High Flow Nasal delivered by myAirvo3 (4 hours minimum and during th 3-minute chair rise test, 30L\u002Fmin, 34°C, identical O2 flow rate as LTOT) for 2 weeks",[15,9],[30],{"name":31,"affiliation":32,"role":33},"Capucine Morélot-Panzini, MD,PhD, Prof","APHP • Assistance Publique des hôpitaux de Paris","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":38},"CONTACT","0142167771","capucine.morelot@aphp.fr",{"name":40,"role":36,"phone":41,"phoneExt":24,"email":42},"Anne Radenne","0142161699","anne.radenne@aphp.fr",{"type":44,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100563508","benefit-of-high-flow-nasal-cannula-on-persistent-dyspnea-in-ild-100563508",false,"NCT06617078","Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild","Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Interstitial Lung Disease: Randomized Multicentric Cross-over Trial","HIGHOXFILD","Inclusion Criteria:\n\n* Intertitial lung disease\n* Persistant dyspnea (mMRC≥3)\n* Long-term oxygen therapy at least for 3 months\n\nExclusion Criteria:\n\n* Chronic respiratory disease (COPD, lung cancer)\n* Pneumothorax,\n* Pneumomediastinum,\n* Active smoker,\n* Patient on non-invasive ventilation or continuous positive airway pressure (CPAP),\n* Pregnancy or breastfeeding,\n* Unable to read or understand questionnaires,\n* No written consent,\n* Patients under guardianship,\n* No health assurance coverage","ALL","18 Years",{"count":56,"type":57},42,"ESTIMATED","INTERVENTIONAL",[60],"NA","The main purpose of this study is to evaluate the effects of high-flow nasal therapy (HFNT) oxygen compared to long-term oxygen therapy (LTOT) on dyspnea and quality of life in intersititial lung disease patients with chronic respiratory failure and persistent breathlessness in whom LTOT has already been initiated.",[63],"ILD",[65,63,66],"Chronic breathlessness","high nasal flow canula","NOT_YET_RECRUITING","2024-09-26",{"date":70,"type":71},"2024-09-27","ACTUAL",{"date":73,"type":57},"2024-10-15",{"date":75,"type":57},"2026-10-15",{"name":5,"class":6}]